Videos

  Clinical Conversations by Experts View all

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer

Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2023

Artificial Intelligence in Prostate Cancer 2022

Featured Videos

The Role of Awareness and Support in Elevating Women in Science - Kristen Scarpato & Svetlana Avulova
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
CAR T and Cellular-Based Therapies - Vivek Narayan
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
Women in Urologic Oncology - Anne K. Schuckman
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Bladder Cancer Highlights - Stephen Williams
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Smarter Screening In Prostate Cancer - Sigrid Carlsson
Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip
Upper Tract Urothelial Carcinoma Highlights - Nima Almassi
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
Darolutamide Approved for Patients with mHSPC - Charles Ryan
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Convatec GentleCath™ Glide No-Touch Catheters - Diane Newman
Uncoated Catheters - Diane Newman
Closed Catheters Systems - Diane Newman
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Self Intermittent Catheters Types - Diane Newman
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Microbiome Research in Bladder Cancer - Laura Bukavina
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
Evidence Supporting the Use of Urinary Catheters for Intermittent Catheterization - Diane Newman
Lessons Learned in the STAMPEDE Trial - Nicholas James
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur
Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano
Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris
Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothelial Carcinoma, Journal Club - Zachary Klaassen and Christopher Wallis
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
PSMA PET/CT Imaging Indications in Prostate Cancer - Phillip Koo, Neal Shore, & Oliver Sartor
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
Urogynecology Controversies: Female Pelvic Medicine and Reconstructive Surgery - Briana Walton
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Women in Science and The Prostate Cancer Foundation - Amina Zoubeidi
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
How I Use Jelmyto™ - Karim Chamie
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen
Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Survivorship in Testicular Cancer - Mary Dunn
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Facing Pelvic Pain - Elise De
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
PSMA-directed Therapy - Scott Tagawa and Michael Morris
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi
A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
In Pursuit of Patient-Centered Care - Karen Knudsen
Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Radium-223 in Clinical Practice - Phillip J. Koo
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Challenges in the Diagnosis and Treatment of UTUC - Peter Black
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Immunotherapy Across Genitourinary Malignancies - James Gulley
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
CARMENA: Practice Changing Strategies for Kidney Cancer
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Clinical Implications of the Abi Race Study: Interview with Dan George
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Defining Bladder Health - Ariana Smith
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

PCF 2022

The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL - Rana McKay
A Historical Perspective on Radioligand Therapy and Novel Treatment Modalities in the Management of mCRPC - Neil H. Bander
The Support and Momentum of the Prostate Cancer Foundation on Prostate Cancer Research and Treatment - Edwin Posadas
Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran
The Impact of Molecular and Genomic Factors on Prostate Cancer Disease Etiology and Health Disparities and The State of Science on Diet and Lifestyle - Lorelei Mucci
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor
Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate - Philip Kantoff
Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer - Saul Priceman
Heterogeneity in Multifocal Prostate Cancer - Simpa Salami
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce
Biological Difference Based on Race: Disparities Throughout the Spectrum of Prostate Cancer - Kosj Yamoah
Disparities in Prostate Cancer: Barriers to Access to Clinical Trials - Elisabeth Heath
Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade
Comprehensively Mapping Epigenetic Alterations Promoting Lineage Plasticity to Develop Blood-based Biomarkers to Predict Treatment Outcomes in Prostate Cancer - Martin Sjöström
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang
Veterans Affair Care Program, Prostate Cancer Biorepository - Isla P. Garraway

Prostate cancer genomic classifier Videos

Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi
Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER Genomic Classifier for Prostate Cancer - Ashley Ross
The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris
PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal Pra
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
The Molecular Biology of Prostate Cancer - Christopher Barbieri
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross
Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment - Ashley Ross
The Use of the Decipher Biopsy Test Prior to Prostatectomy - Ashley Ross
Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross
Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray
The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng
Data from the RTOG 9601 Study: Treating Prostate Cancer Patients with Low-Volume Disease - Daniel Spratt

Latest Videos

Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz
The "Get Moving Trial" Home-based Pre and Rehabilitation Intervention for Muscle-invasive Bladder Cancer, BCAN Translational Clinical Trial Award - Sarah Psutka
The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky
Neoadjuvant Versus Adjuvant Chemotherapy in Patients With Clinically Node-positive UTUC Who Underwent a Radical Nephroureterectomy - Karan Jatwani
The Role of Adjuvant Chemotherapy, Versus Observation, in Patients With Upper Urinary Tracts With Variant Histology Undergoing a Radical Nephroureterectomy - Karan Jatwani
Advances in Advanced Prostate Cancer - Silke Gillessen
Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar
Testosterone Recovery in Patients With Prostate Cancer Treated With Radiotherapy Plus ADT - Tanya Dorff
Brain Metastases From Renal Cell Carcinoma Treated With First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium - Kosuke Takemura
Overall Survival and Efficacy Results of Second-line Treatment for Patients With Metastatic Clear Cell Renal Cell Carcinoma, BIONIKK Trial -Yann Vano
Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center - Thomas Hope
A Novel Patient-reported Outcome Measure for Patients With Prostate Cancer Receiving Radionuclide Therapy: FACT-RNT - Lisa Gudenkauf
Real World Implementation of Online Versus in-person Community-based Continence Promotion - Madeline Moureau
Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng
Smartphone-based Self-care Education Program for Women With Interstitial Cystitis - Edward Kim
Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA - Jones Nauseef
Developing Centers of Excellence for Treatment of Major Urological Cancers in Australia - Manish Patel
An Integrative Platform of Whole Genome and Transcriptome Sequencing to Identify Additional Targets in Advanced Prostate Cancer - Jones Nauseef
The Association Between FGFR3 Alterations and Response to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma - Gopa Iyer
Clinicopathological or Radiological Factors That May Predict a Diagnosis of Upper Urinary Tract Urothelial Cell Carcinoma Without the Delay for Diagnostic Ureteroscopy - Alexander Laird

Bladder Cancer Videos

Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz
The "Get Moving Trial" Home-based Pre and Rehabilitation Intervention for Muscle-invasive Bladder Cancer, BCAN Translational Clinical Trial Award - Sarah Psutka
Developing Centers of Excellence for Treatment of Major Urological Cancers in Australia - Manish Patel
Gene Expression and Molecular Subtyping in GU Cancers Presentation - Ewan Gibb
EAU Guidelines on Thromboprophylaxis in Urological Surgery - Kari Tikkinen
Risk of Progression in NIMBC Patients Treated with BCG Overestimated by Updated European Association of Urology (EAU) Prognostic Factor Risk Groups - Niyati Lobo
From Science to Clinical Utility: Cxbladder Monitor - Bladder Cancer Surveillance for Patients with Urothelial Carcinoma - Tamer Aboushwareb, Neal Shore & Josh Meeks
Using Artificial Intelligence (AI) to Identify and Diagnose Bladder Cancer - Hikmat Al-Ahmadie & Olivier Elemento
MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James
From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria - Tamer Aboushwareb, Neal Shore & Josh Meeks
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
Women in Urologic Oncology - Anne K. Schuckman
Bladder Cancer Highlights - Stephen Williams
Bladder Cancer in the Older Adult Population: Special Considerations - Tullika Garg
Highlighting 25 Years of the International Bladder Cancer Network (IBCN) - Barton Grossman
Gender Differences in Bladder Cancer - Lauren Cooley
Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
Microbiome Research in Bladder Cancer - Laura Bukavina
Realities of Bladder Cancer In Women - Sima Porten, Kristen Scarpato, Svetlana Avulova & Anne Schuckman
Busting Common Myths Regarding Bladder Preservation for Muscle Invasive Bladder Cancer - Nick James & Ananya Choudhury
Urethral Recurrence after Radical Cystectomy for Bladder Cancer - Ekaterina Laukhtina
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
Comparative Effectiveness of Radical Cystectomy and Trimodality Therapy for Muscle-Invasive Bladder Cancer – Boris Gershman
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumor - Sia Daneshmand
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Mucosal Differences in The Bladder - Molly Ingersoll
Translational Research in Bladder Cancer, A BCAN Young Investigator - Phillip Abbosh
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
Urologists, You’ll Never Walk Alone! - Gianluca Giannarini
Systemic Therapies in Advanced Bladder Cancer - Noah Hahn
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams
ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen
Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas
Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
Germline and Somatic Interactions in Bladder Cancer - Bishoy Faltas
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar
A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg
Update on Urine Markers for Hematuria and Bladder Cancer - Yair Lotan
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer - Lars Dyrskjøt
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2020 Update - Marek Babjuk
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar
A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
Vicineum for High-Risk Non-Muscle-Invasive BCG Unresponsive Bladder Cancer - Rian J. Dickstein
The Role of the PD-L1 Checkpoint in BCG Resistance - Max Kates
Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar
T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar
Clinically Node Positive Bladder Cancer and The Timing of Surgery - Neema Navai
The Management of Bladder Cancer During Pregnancy - Makarand Khochikar
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
Urinary Diversion in Women Following Radical Cystectomy - Renu Eapen
Radical Cystectomy and The Importance of Oncological Concepts in Surgical Approach - Rafael Sanchez Salas
T2 N0 M0 Muscle-invasive Bladder Cancer Patient Case - Makarand Khochikar
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
Blue Light Cystoscopy with Cysview®: Tips and Tricks - Anne Schuckman
The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan
AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten
Macro and Microeconomics of Blue Light Cystoscopy with CYSVIEW® in Non-Muscle Invasive Bladder Cancer - Stephen Williams
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf
Role of Blue Light Cystoscopy in Bladder Cancer Management - Trinity Bivalacqua
Bladder Preservation Protocols for Muscle-Invasive Urothelial Carcinoma - Arjun Balar
Weathering the Current BCG Shortage Crisis - Michael O’Donnell
Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits
Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen
Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks
Research and Clinical Practice Strategies Due to the BCG Shortage - Sam S. Chang
Bladder Cancer Research That Impacts Urology Clinical Practice - Josh Meeks
The Benefits of Early Recovery After Radical Cystectomy (ERAS) Protocols - Sima Porten
The BCG Shortage - What To Do In This Setting - Joshua Meeks
Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Badrinath Konety
Guided Imagery for Urologic Surgery - Sima Porten
Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan
Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams
Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan
Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman
Toxicity Management with Checkpoint Inhibitor Therapy - Thomas Powles
Bladder Cancer in Women - Morgan Roupret
BCG Shortage An Update - Jonathan Rubenstein
The Role of the Surgeon in the Treatment of Bladder Cancer - Jens Bedke
Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles
What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks
ERAS in Bladder Cancer - Sia Daneshmand
The State of Immunotherapy in Bladder Cancer - Thomas Powles
Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits
Optimal Surgical Approaches in Cystectomy - Piyush Agarwal
Improving Outcomes in Bladder Cancer - Arnulf Stenzl
The Role of the Surgeon in the Management of Metastatic Bladder Cancer - Brant Inman
Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer - Stephen B Williams
Defining BCG-Unresponsive and The Pathway to Clinical Trials in Treating NMIBC - Ashish Kamat
BCG Shortage 2019: Managing Through Treatment and Reimbursement Issues - Neal Shore, Ashish Kamat, and Jonathan Rubenstein
2019 BCG Shortage-Perspectives from Josh Meeks
Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten
Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand
Patient Reported Outcomes in the Use of Blue Light Cystoscopy in the Surveillance of Bladder Cancer - Angela B. Smith
Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat
Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn
Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat
Keynote-057 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Evan Yu
Is There Still a Role for Chemotherapy in Bladder and Prostate Cancer - Maria De Santis
Immunotherapy in Bladder Cancer - Arjun Balar
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane
Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas
FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas
Update in Immuno-Oncology in Bladder Cancer - Arjun Balar
Journey from Oncologist to Cancer Survivor and Patient Advocate - Burton Needles
Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat
Helping Patients Cope after Major Interventions for Bladder Cancer Therapy
The Changing Landscape in Advanced Bladder Cancer - Tom Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Enhanced Recovery After Surgery (ERAS) for Radical Cystectomy: History, Rationale and Programmatic Implementation - Thomas Guzzo
Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde
Enhanced Recovery After Surgery (ERAS) Radical Cystectomy and Urinary Diversion- Ashish Kamat

Recent Conference Coverage

  Conference Highlights Written by Physician-Scientist
AUA 2023 Conference Highlights
View all AUA 2023 coverage
EAU 2023 Conference Highlights
View all EAU 2023 coverage

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
Advanced Prostate Cancer
View all Advanced Prostate Cancer Center of Excellence
mHSPC
View all mHSPC Center of Excellence

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

Bladder Cancer Detection

Reno, Nevada (UroToday.com) -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?” in Urologic Oncology this week. The research objective was to quantify the clinical and economic impact of the incorporation of BLC in the management of NMIBC in ambulatory surgical centers (ASCs) considering 2022 Center for Medicare Services (CMS) patient-physician coverage and reimbursement.

Clinical Application And Utility Of PYLARIFY

Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain.

ARAMIS Trial

Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit.

ARASENS Trial

Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.

VISION Trial

Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.